Delighted to have opportunity yesterday to speak with @GRASPtweets patient advocate mentors, #MBC survivors, oncologists & scientists about investigator-initiated trial @BrownOncology BrUOG 387 @BrownUCancer @BrownMedicine @BrownUniversity @LifespanHlthSys @carenewengland @OncoAlert
Our trial builds on >15 year effort in #eldeirylab first-in-human combo ER/PR+ Her2- breast cancer & tumors w/ Rb loss. Presented @ASCO #ASCO23 appreciate questions & discussion led by GRASP co-founder @itsnot_pink

RT @JohnEbbenMDPhD
A huge thank you to @PTarantinoMD & @drsarahsam for presenting a whirlwind #TumorBoardTuesday. Amazing to see how we're learning to better use CDK4/6i in #mBC, and how #precisiononcology provides new options in the 2L setting. Check out the summary below. Happy weekend! https://twitter.com/JohnEbbenMDPhD/status/1631674649305030656

A huge thank you to @PTarantinoMD & @drsarahsam for presenting a whirlwind #TumorBoardTuesday. Amazing to see how we're learning to better use CDK4/6i in #mBC, and how #precisiononcology provides new options in the 2L setting. Check out the summary below. Happy weekend!
---
RT @JohnEbbenMDPhD
@TumorBoardTues @drsarahsam @PTarantinoMD @stolaney1 @MPishvaian @BreastCaupdates @BCRFcure @BCAction @LivingBeyondBC @RenoHemonc 3/5 #TumorBo…
https://twitter.com/JohnEbbenMDPhD/status/1631674649305030656

RT @JohnEbbenMDPhD
@TumorBoardTues @drsarahsam @PTarantinoMD @stolaney1 @MPishvaian @BreastCaupdates @BCRFcure @BCAction @LivingBeyondBC @RenoHemonc 3/5 #TumorBoardTuesday
Case🎀

🎥 TBT in a video: HR+ #mBC tx has changed significantly, esp in 2L setting.

Check out this SHORT video w algorithm to approach tx after progression on CDK4/6i:

A bigger and bigger role for 🎯 medicine to select next best therapy!

RT @JohnEbbenMDPhD
@TumorBoardTues @drsarahsam @PTarantinoMD @stolaney1 @MPishvaian @BreastCaupdates @BCRFcure @BCAction @LivingBeyondBC @RenoHemonc 3/5 #TumorBoardTuesday
Case🎀

🎥 TBT in a video: HR+ #mBC tx has changed significantly, esp in 2L setting.

Check out this SHORT video w algorithm to approach tx after progression on CDK4/6i:

A bigger and bigger role for 🎯 medicine to select next best therapy!

RT @JohnEbbenMDPhD
@TumorBoardTues @drsarahsam @PTarantinoMD @stolaney1 @MPishvaian @BreastCaupdates @BCRFcure @BCAction @LivingBeyondBC @RenoHemonc 3/5 #TumorBoardTuesday
Case🎀

🎥 TBT in a video: HR+ #mBC tx has changed significantly, esp in 2L setting.

Check out this SHORT video w algorithm to approach tx after progression on CDK4/6i:

A bigger and bigger role for 🎯 medicine to select next best therapy!

RT @JohnEbbenMDPhD
@TumorBoardTues @drsarahsam @PTarantinoMD @stolaney1 @MPishvaian @BreastCaupdates @BCRFcure @BCAction @LivingBeyondBC @RenoHemonc 3/5 #TumorBoardTuesday
Case🎀

🎥 TBT in a video: HR+ #mBC tx has changed significantly, esp in 2L setting.

Check out this SHORT video w algorithm to approach tx after progression on CDK4/6i:

A bigger and bigger role for 🎯 medicine to select next best therapy!

T- NOW! @PTarantinoMD & @drsarahsam bring us the latest in CDK4/6 inhibition in #mBC. Join #TumorBoardTuesday by following @TumorBoardTues.
---
RT @TumorBoardTues
#TumorBoardTuesday
👉B4 @PTarantinoMD & @drsarahsam🗣️CDK4/6⛔️for #breastcancer test your🧠w/ this CME❓
#PreTest❓Free #CME🔗http://integrityce.com/tbt

🤔Which 1L Tx would you choose for a 54yo postmenopausal♀️with mBC, ER+HER2-, s/p TC➕XRT, letrozole x 5yrs completed in 2018?
https://twitter.com/TumorBoardTues/status/1630591224196534272

RT @JohnEbbenMDPhD
@TumorBoardTues @drteplinsky @stolaney1 @hoperugo @dradityabardia @BreastCaupdates @BCRFcure @MBCNbuzz 3/5 #TumorBoardTuesday
🎥 TBT in a video
New 1L T-DXd option for patients w #mBC (HER2 low, ER/PR-).

T-DXd is an antibody drug conjugate (ADC), tethering deruxtecan payload to HER2 ab. Improvements over chemo in mOS and PFS, but watch carefully for ILD and all toxicities!

RT @drteplinsky
8/22 #TumorBoardTuesday #MBC #BCSM
👩🏻‍🏫Mini tweetorial 6

✨Destiny-Breast 04✨

📌Results

🎉Based on results - T-DXd approved as first 🎯 therapy for HER2-low unresectable and/or metastatic #BreastCancer in 8/2022 #MBC

RT @drteplinsky
8/22 #TumorBoardTuesday #MBC #BCSM
👩🏻‍🏫Mini tweetorial 6

✨Destiny-Breast 04✨

📌Results

🎉Based on results - T-DXd approved as first 🎯 therapy for HER2-low unresectable and/or metastatic #BreastCancer in 8/2022 #MBC

RT @drteplinsky
8/22 #TumorBoardTuesday #MBC #BCSM
👩🏻‍🏫Mini tweetorial 6

✨Destiny-Breast 04✨

📌Results

🎉Based on results - T-DXd approved as first 🎯 therapy for HER2-low unresectable and/or metastatic #BreastCancer in 8/2022 #MBC

RT @drteplinsky
8/22 #TumorBoardTuesday #MBC #BCSM
👩🏻‍🏫Mini tweetorial 6

✨Destiny-Breast 04✨

📌Results

🎉Based on results - T-DXd approved as first 🎯 therapy for HER2-low unresectable and/or metastatic #BreastCancer in 8/2022 #MBC

Dr Ashley Pariser, Assistant Professor, is spearheading our #BreastOnc #Survivorship program with an award from #DavisBremer for the ECHO study as well as expanding the OSU #LivingWellWithAdvancedBreastCancer program #bcsm #mBC

Dr Robert Wesolowski, Associate Professor, presented data from the Phase 1 Gedatolisib + Palbociclib + Endocrine Tx in #mBC with PIK3CA mutation at #SABCS22 #bcsm @OSUWexMed @OSUCCC_James He leads our Phase 1 efforts

RT @JohnEbbenMDPhD
Thanks to @quirogad & @jane_meisel for taking us through the latest in #PARPi tx in HER2- #mBC.

🔑 to ⬆️access to germline 🧬🧪 & to increasingly think in terms of patient-centered outcomes & QoL.
Inspired this holiday season by the potential to improve outcomes for patients! https://twitter.com/JohnEbbenMDPhD/status/1606104321032085511

RT @JohnEbbenMDPhD
@TumorBoardTues @jane_meisel @quirogad @MPishvaian @BreastCaupdates @BreastCancerNow @TNBCFoundation @ArielleMedford 2/5 #TumorBoardTuesday
Case🎀
🎥 TBT in a video
Take a 👀at our quick, high-yield 🎥 summary of PARPi in HER2- #mBC.

🔹Tx needs to be personalized to the patient; family history is very important!
🔹Consider PFS and QoL/pt centered outcomes

Need to balance many trade-offs ⚖️!

RT @JohnEbbenMDPhD
@TumorBoardTues @jane_meisel @quirogad @MPishvaian @BreastCaupdates @BreastCancerNow @TNBCFoundation @ArielleMedford 3/5 #TumorBoardTuesday
Thurs Case🎀

📷 TBT in an image

All pts w HER2- #mBC SHOULD receive germline genetics! Involvement of genetics team EARLY is highly advised.

PARPi= improved PFS, QoL. Watch for 🩸cytopenias, 🤢nausea/vomiting. Less common AEs= MDS/AML and pneumonitis.

RT @JohnEbbenMDPhD
@TumorBoardTues @jane_meisel @quirogad @MPishvaian @BreastCaupdates @BreastCancerNow @TNBCFoundation @ArielleMedford @drteplinsky @EricaMarieRomn1 @jacobadashek @stolaney1 @MarkRobsonMD 5/5 #TumorBoardTuesday
Thurs Case🎀

🙏Ongoing trials eval PARPi w other HRDm
🤔How can we ⬆️germline testing for pts w HER2- #mBC?

➡️Join us on 01/10/23 when @PGrivasMDPhD @rafee_talukder discuss #UrothelialCancer & FGFR3 alterations. Happy holidays!

RT @JohnEbbenMDPhD
Thanks to @quirogad & @jane_meisel for taking us through the latest in #PARPi tx in HER2- #mBC.

🔑 to ⬆️access to germline 🧬🧪 & to increasingly think in terms of patient-centered outcomes & QoL.
Inspired this holiday season by the potential to improve outcomes for patients! https://twitter.com/JohnEbbenMDPhD/status/1606104321032085511